MIV Therapeutics Inc.


in
MIV Therapeutics Inc. reported continued excellent results of VESTAsync(TM), a polymer-free drug-eluting stent, at a twelve-month clinical follow up for all fifteen patients in its first-in-man (FIM) VESTASYNC I Trial. Patients remain free of any major adverse cardiac events or MACE. MIV also announced that it now has accumulated nine-month intravascular ultrasound (IVUS) and Quantitative Coronary Angiography (QCA) for all fifteen patients enrolled in the VESTASYNC I trial. This data showed no statistical difference from the safety and efficacy data reported at four months. Patients in the VESTASYNC I trial will be followed for two years and the company expects to continue to provide updates throughout the duration of the follow up period. In addition to the ongoing VESTASYNC I trial, MIV continues to enroll patients in the VESTASYNC II trial. The VESTASYNC II trial is a 120 patient randomized controlled study designed to demonstrate the safety and efficacy of the VESTAsync(TM) stent in a larger group of patients.